Quantitative profiling of the effects of vanoxerine on human cardiac ion channels and its application to cardiac risk

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Obejero Paz, Carlos A ^a   Bruening Wright, Andrew ^a   Kramer, James ^a   Hawryluk, Peter ^a   Tatalovic, Milos ^a   Dittrich, Howard C ^b   Brown, Arthur M ^a,b  

^a ChanTest   (United States)

^b Laguna Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEPRIDIL; DOFETILIDE; ION CHANNEL; PHENETHYLAMINE DERIVATIVE; PIPERAZINE DERIVATIVE; POTASSIUM CHANNEL HERG; SULFONAMIDE; VANOXERINE; VERAPAMIL;

ACTION POTENTIAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CHO CELL LINE; COMPUTER SIMULATION; CRICETULUS; DRUG EFFECTS; HEART; HEK293 CELL LINE; HUMAN; IC50; MEMBRANE POTENTIAL; METABOLISM; PATCH CLAMP TECHNIQUE; PHYSIOLOGY;

ACTION POTENTIALS; ANIMALS; BEPRIDIL; CHO CELLS; COMPUTER SIMULATION; CRICETULUS; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; ION CHANNELS; MEMBRANE POTENTIALS; MODELS, BIOLOGICAL; MYOCARDIUM; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PHENETHYLAMINES; PIPERAZINES; SULFONAMIDES; VERAPAMIL;

EID: 84948771682     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep17623     Document Type: Article

References (46)

1. Sgaard, U. et al. A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects. Int. Clin. Psychopharmacol. 5, 237-251 (1990).
2. Preti, A. Vanoxerine National Institute on Drug Abuse. Curr. Opin. Investig. Drugs. 1, 241-251 (2000).
3. Dittrich, H. C. et al. COR-ART: A multicenter, randomized, double-blind, placebo- controlled dose ranging study to evaluate single oral doses of vanoxerine for conversion of recent onset atrial fibrillation or flutter to normal sinus rhythm. Heart Rhythm. 12, 1105-1112 (2015).
4. Lacerda, A. E., Kuryshev, Y. A., Yan, G. X., Waldo, A. L. & Brown, A. M. Vanoxerine: cellular mechanism of a new antiarrhythmic. J. Cardiovasc. Electrophysiol. 21, 301-310 (2010).
5. ICH. Harmonised Tripartite Guideline S7B. Non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. Step 4 Version, May 2005. Available at: http://www.ich.org/fileadmin/Public- Web-Site/ICH-Products/Guidelines/Safety/S7B/Step4/S7B- Guideline.pdf. (Accessed 20 February 2015).
6. ICH. Harmonised Tripartite Guideline E14. Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. Step 4 Version, May 2005. Available at: http://www.ich.org/fileadmin/Public-Web-Site/ICH- Products/Guidelines/Efficacy/E14/E14-Guid eline.pdf. (Accessed 20 February 2015).
7. Redfern, W. S. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45 (2003).
8. Kramer, J. et al. MICE models: superior to the hERG model in predicting torsade de pointes. Sci. Rep. 3, 2100 (2013).
9. Matsumoto, N. et al. Vanoxerine, a new drug for terminating atrial fibrillation and flutter. J. Cardiovasc. Electrophysiol. 21, 311-319 (2010).
10. Cakulev, I. et al. Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results. J. Cardiovasc. Electrophysiol. 22, 1266-1273 (2011).
11. Rampe, D. & Brown, A. M. A history of the role of the hERG channel in cardiac risk assessment. J. Pharmacol. Toxicol. Methods. 68, 13-22 (2013).
12. OHara, T., Virág, L., Varró, A. & Rudy, Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS. Comput. Biol. 7, e1002061 (2011).
13. Suttorp, M. J., Kingma, J. H., Lie-A-Huen, L. & Mast, E. G. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am. J. Cardiol. 63, 693-696 (1989).
14. Sager, P. T., Gintant, G., Turner, J. R., Pettit, S. & Stockbridge, N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am. Heart J. 167, 292-300 (2014).
15. De Bruin, M. L., Pettersson, M., Meyboom, R. H., Hoes, A. W. & Leufkens, H. G. Anti- hERG activity and the risk of druginduced arrhythmias and sudden death. Eur. Heart J. 26, 590-597 (2005).
16. Mirams, G. R. et al. Simulation of multiple ion channel block provides improved early prediction of compounds clinical torsadogenic risk. Cardiovasc. Res. 91, 53-61 (2011).
17. Mirams, G. R. et al. Prediction of thorough QT study results using action potential simulations based on ion channel screens. J. Pharmacol. Toxicol. Methods. 70, 246-254 (2014).
18. Coumel, P. Safety of bepridil: from review of the European data. Am. J. Cardiol. 69, 75D-78D (1992).
19. Wible, B. A. et al. HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods. 52, 136-145 (2005).
20. Nielsen-Kudsk, F., Siggaard, C., Nielsen, C. B. & Mellemkjaer, S. Myocardial accumulation kinetics and pharmacodynamics in the isolated rabbit heart of a new inhibitor of dopamine reuptake, GBR 12909. Pharmacol. Toxicol. 66, 197-202 (1990).
21. Nielsen-Kudsk, F., Askholt, J. & Jakobsen, P. Bepridil, myocardial accumulation kinetics and dynamic effects in the isolated rabbit heart. Pharmacol. Toxicol. 63, 122-128 (1988).
22. Varkevisser, R. et al. Structure-activity relationships of pentamidine-affected ion channel trafficking and dofetilide mediated rescue. Br. J. Pharmacol. 169, 1322-1334 (2013).
23. Ma, J. et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006-H2017 (2011).
24. Scheel, O. et al. Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology. Assay Drug. Dev. Technol. 12, 457-469 (2014).
25. Kirsch, G., Obejero-Paz, C. & Bruening-Wright, A. Functional characterization of human stem cell-derived cardiomyocytes. Curr. Protoc. Pharmacol. 64, 11-12 (2014).
26. Kang, L. et al. Bepridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity. Br. J. Pharmacol. 157, 404-414 (2009).
27. Itoh, H., Ishikawa, T. & Hidaka, H. Effects on calmodulin of bepridil, an antianginal agent. J. Pharmacol. Exp. Ther. 230, 737-741 (1984).
28. Muehlbacher, M., Tripal, P., Roas, F. & Kornhuber, J. Identification of drugs inducing phospholipidosis by novel in vitro data. ChemMedChem. 7, 1925-1934 (2012).
29. Decker, K. F. & Rudy, Y. Ionic mechanisms of electrophysiological heterogeneity and conduction block in the infarct border zone. Am. J. Physiol. Heart Circ. Physiol. 299, 1588-1597 (2010).
30. Kirsch, G. E. et al. Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J. Pharmacol. Toxicol. Methods. 50, 93-101 (2004).
31. Zhang, S., Zhou, Z., Gong, Q., Makielski, J. C. & January, C. T. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ. Res. 84, 989-998 (1999).
32. Alexandrou, A. J. et al. Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin. Br. J. Pharmacol. 147, 905-916 (2006).
33. Milnes, J. T., Witchel, H. J., Leaney, J. L., Leishman, D. J. & Hancox, J. C. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 C: Cisapride versus dofetilide. J. Pharmacol. Toxicol. Methods. 61, 178-191 (2010).
34. Song, Y., Shryock, J. C., Wu, L. & Belardinelli, L. Antagonism by ranolazine of the pro- arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol. 44, 192-199 (2004).
35. Luo, A. et al. Larger late sodium current density as well as greater sensitivities to ATX II and ranolazine in rabbit left atrial than left ventricular myocytes. Am. J. Physiol. Heart Circ. Physiol. 306, H455-H461 (2014).
36. Antzelevitch, C. et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 110, 904-910 (2004).
37. Rajamani, S., El-Bizri, N., Shryock, J. C., Makielski, J. C. & Belardinelli, L. Use- dependent block of cardiac late Na+ current by ranolazine. Heart Rhythm. 6, 1625-1631 (2009).
38. Wu, L. et al. Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc. Res. 77, 481-488 (2008).
39. Maltsev, V. A., Sabbah, H. N. & Undrovinas, A. I. Late sodium current is a novel target for amiodarone: studies in failing human myocardium. J. Mol. Cell. Cardiol. 33, 923-932 (2001).
40. 2+ current. Circ. Res. 64, 977-990 (1989).
41. Qu, Z. et al. Early afterdepolarizations in cardiac myocytes: beyond reduced repolarization reserve. Cardiovasc. Res. 99, 6-15 (2013).
42. Pandit, S. V. & Jalife, J. Rotors and the dynamics of cardiac fibrillation. Circ. Res. 112, 849-862 (2013).
43. Rae, J., Cooper, K., Gates, P. & Watsky, M. Low access resistance perforated patch recordings using amphotericin B. J. Neurosci. Methods. 37, 15-26 (1991).
44. Tajima, Y., Ono, K. & Akaike, N. Perforated patch-clamp recording in cardiac myocytes using cation-selective ionophore gramicidin. Am. J. Physiol. 271, C524-C532 (1996).
45. Brennan, T., Fink, M. & Rodriguez, B. Multiscale modelling of drug-induced effects on cardiac electrophysiological activity. Eur. J. Pharm. Sci. 36, 62-77 (2009).
46. Ficker, E., Dennis, A. T., Wang, L. & Brown, A. M. Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res. 92, e87-e100 (2003).